



HEALTHY, FIT & STRONG DECEMBER 2006


2 36.6 AT GLANCE


We strive to be
Russia's leading
health & beauty
retailer and to
become the
preferred source of
medicines and
health & beauty
products for Russian
consumers

USD millions









3 GROWTH DRIVERS

GDP per Capita 2006E \$6,800

☐ Growing disposable income pushes consumption up

Disposable Income CAGR 14-16%

■ Booming H&B and Pharma industry followed by changes in consumer's behaviour

Pharma market 2006E \$9.9bln

☐ Improving economy in the regions provide for better opportunities of consolidation

Pharma market CAGR 10-12%

□ Scale effect together with internal improvements in operations management ensure higher future profitability

Source: Investment banks researches, Pharmexpert

CAGR for `05-`11

4 STORES GROWTH



RX

H&B

OTC


Others

Parapharma

Organic growth

Acquisitions

■ b-o-p



5 REGIONAL EXPANSION

Business-Units

MOSCOW 269
URALS 177
POVOLJIE 163
SOUTH 77
NORTH-WEST 46
WEST. SIBERIA 25

the Company reaches out to every Russian city with a population of over 500K people to enjoy 10-20% of the region's pharmacy retail market N. Novgorod 30%

Moscow 15% local Market share

Perm
40%
local Market share


Ufa 30% local Market share

Rostov-on-Don 30%

Orenburg
25%
local Market share

currently operating 757 pharmacies in 23 regions Murmansk S.-Petersburg Yaroslavl Kirov Moscow Novgoro Perm Yekaterinburg Kazan **Rostov Omsk** Volgograd Krasnodar Saratov Samara Novosibirsk **Orenburg**

6 KEY PERFORMANCE INDICATORS



Index

Moscow=100

Index

Moscow=100

Index


Moscow=100

^{*} Please note, that in 2005 the Company regrouped certain business-units

7 COMPETITION

Regional
penetration will be
achieved both
through organic
openings and
acquisitions of the
regional chains

This is subject to successful competition with a few other chains developing nationwide



Source: Pharmexpert, 9M 2006

8 BRAND & CUSTOMERS




36.6 membered
MALINA - new
loyalty program to
gather leading
companies of the
Russian consumer
sector


Source: Gallup Media Survey'06

A/R/M/I-Marketing data,
June. 2006

Brand awareness



Shopping experience



9 DIFFERENTIATION

New projects launched by

36.6 aimed to differentiate our product assortment and to obtain higher gross margins

Cosmetics centers

located in over 50 major pharmacies



Exclusive offerings

300 SKU's of Boots products are sold countrywide



Private Label

over 50 SKU's and 150 in the pipeline



Optics
20 opticians
departments



10 DIVERSIFICATION

MEDICAL SERVICES



In July 2006 we acquired one of the best Moscow private clinics providing medical, surgical and dental services through EMC & EDC as well as full-scale laboratory

FY`06(E) SALES EBITDA

\$20mln 20%

Market

- fragmented with no potential core for consolidation
- non-satiated rapidly growing demand
- disturbed national healthcare system

Rationale/Strategy

 realize synergies between retail and medical services businesses by launching a chained operator in "masstige" market segment

11 BOARD OF DIRECTORS

Decision making is ensured by the balanced opinion of both shareholders and that of independent directors

Sergey KRIVOSHEEV Chairman, Co-founder

Artem BEKTEMIROV CEO, Co-founder

Michael OBERMAYER Independent director, Director Emeritus of McKinsey & Company

Vassily RUDOMINO, Independent director, Partner in ALRUD law firm Vladimir STOLIN, Independent director, Chairman in ECOPSY consulting firm

12 MANAGEMENT STRUCTURE

Planning and operational controls are performed across the regional business units and product categories

Brand integrity and management as well as strategic business development and expansion are corporate major priorities

ARTEM BEKTEMIROV

ANTON PARKANSKY Managing director

DMITRY GODUNOVOperations
1st Deputy MD

ALEXANDRA KOZHAEVA Commercial director **SBORETS YULIA** CFO

OLGA ALTUNINA Human Resources

BORIS RYABOV
Business Technology
Development

DMITRY KOZOREZOV Medical director VICTOR VASILIEV Legal Council

OLEG ANIKINStrategy

ANDREI SLIVCHENKO
Corporate Finance
& Investor Relations

DARYA KAPLUNOVAMarketing

CATEGORY DIRECTORS

REGIONAL BUSINESS UNITS

APPENDIXFINANCIALS & ANALYSIS

Please note: reporting under IFRS since 2002 auditor Deloitte 9M 2006 financials are IFRS unaudited data by segments requires certain adjustments

14 INCOME STATEMENT CONSOLIDATED

	9M06	9M05	06/05	2005	2004	2003	2002
NET SALES	346.9	210.7	65%	305.2	211.0	147.8	118.7
GROSS PROFIT	121.8	81.7	49%	117.8	80.2	59.8	46.0
EBITDA	12.3	15.0	-18%	21.1	18.5	13.6	15.1
	3.6%	7.1%		6.9%	8.8%	9.2%	12.7%
OPERATING INCOME	3.9	7.7	-49%	13.3	11.5	8.4	10.4
NET INCOME	41.5	-4.8	n/a	8.3	0.7	1.0	3.3
	12.0%	-2.3%		2.7%	0.3%	0.7%	2.8%


15 BALANCE SHEET

CONSOLIDATED

N-CURRENT ASSETS
CURRENT ASSETS
TOTAL ASSETS
EQUITY
TOTAL DEBT
C-NT LIABILITIES*

9M06	2005	2004	2003	2002
247.7	125.3	99.8	60.1	45.9
190.6	119.4	72.5	53.0	38.8
438.3	244.7	172.3	113.1	84.7
92.2	48.4	43.5	40.2	24.7
196.0	109.9	80.4	43.1	36.0
102.3	64.2	40.0	24.9	20.1

16 BALANCE SHEET CONSOLIDATED



17 INCOME STATEMENT RETAIL

	9M06	9M05	06/05	2005	2004	2003	2002
NET SALES	250.2	141.1	77%	203.2	134.3	81.9	58.8
GROSS PROFIT	74.7	46.4	61%	67.2	45.4	26.3	19.2
GROSS MARGIN	29.8%	32.9%		33.1%	33.8%	32.1%	33%
EBITDA	-3.6	2.1	n/a	2.6	6.4	1.8	2.6
	-1.4%	1.5%		1.3%	4.8%	2.2%	4.4%
OPERATING INCOME	-4.6	-0.2	n/a	-3.0	2.6	-0.2	0.9

18 AGING PHARMACIES PERFORMANCE

Same store sales were up 19.8% yoy in the 9M of 2006

OLD PHARMACIES

pharmacies opened before 2005


NEW PHARMACIES

pharmacies opened in 2005

ALL PHARMACIES



PHARMACY PROFIT
MARGIN



19 BALANCE SHEET RETAIL


N-CURRENT ASSETS
CURRENT ASSETS
TOTAL ASSETS
LONG-TERM LIAB.

C-NT LIABILITIES

9M06	2005	2004	2003	2002
186.0	85.4	59.5	21.9	15.7
96.8	52.4	29.1	15.6	13.1
282.8	137.8	88.6	37.4	28.8
4.8	4.6	4.7	1.9	11.1
78.8	47.2	27.3	35.3	15.2

20 SG&AE RETAIL

- OTHER
- ADVERTISING
- RENTALS
- PERSONNEL



21 INCOME STATEMENT VEROPHARM

	9M06	9M05	06/05	2005	2004	2003	2002
NET SALES	70.7	55.7	27%	79.4	59.9	52.8	43.9
GROSS PROFIT	41.6	33.2	25%	47.0	32.7	31.3	23.4
GROSS MARGIN	58.8%	59.6%		59.2%	54.5%	59.2%	53.3%
EBITDA	19.0	15.8	20%	23.3	17.8	15.7	13.5
	26.9%	28.4%		29.3%	29.7%	29.7%	30.9%
OPERATING INCOME	17.0	12.7	34%	21.2	14.8	12.7	10.5

22 BALANCE SHEET

VEROPHARM

	9M06	2005	2004	2003	2002
N-CURRENT ASSETS	38.6	35.5	35.9	34.4	31.2
CURRENT ASSETS	78.5	58.4	38.7	32.4	23.4
TOTAL ASSETS	117.1	93.9	74.6	66.8	54.5
C-NT LIABILITIES	15.1	13.6	20.4	20.1	6.5

23 DISCLAIMER

THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION.

This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity in any jurisdiction. Neither this presentation nor any part thereof, nor the fact of its distribution, shall form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

24 HEALTHY, FIT & STRONG

Address: 105082, Moscow, Bolshaya Pochtovaya 36

Tel.: +7 (495) 792-5207

Fax: +7 (495) 792-5206

E-mail: ir@oao366.ru

www.pharmacychain366.com